News archive
GLP‑1 news from 2011
1 dated, sourced GLP-1 developments from 2011: approvals, trial results, prices, lawsuits, compounding and culture.
- Business
Zyprexa loses US patent protection, opening the "Years YZ" patent cliff
Zyprexa, Cymbalta, Gemzar and Evista lost exclusivity between 2011 and 2014. Revenue fell from $24.3 billion in 2011 to $19.6 billion in 2014. Lilly refused to merge and spent through the trough on research.